126 results
8-K
EX-99.1
BCLI
Brainstorm Cell Therapeutics, Inc.
16 Apr 24
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
9:31pm
and strategic insights in this new role.”
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a leading developer of innovative
8-K
BCLI
Brainstorm Cell Therapeutics, Inc.
16 Apr 24
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
9:31pm
innovative development platforms to increase productivity. Prior to her role at Biogen, Dr. Lindborg worked at Eli Lilly & Company, where she held
8-K
EX-99.1
BCLI
Brainstorm Cell Therapeutics, Inc.
11 Apr 24
Other Events
6:10am
developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. BrainStorm holds the rights to clinical
8-K
EX-99.1
BCLI
Brainstorm Cell Therapeutics, Inc.
9 Apr 24
BrainStorm Cell Therapeutics Announces Agreement with FDA on a
6:05am
Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. BrainStorm holds
8-K
EX-99.1
3cwmoamg1ysj
1 Apr 24
BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update
8:15am
8-K
EX-99.1
dr6o tzu1in
20 Dec 23
BrainStorm Issues 2023 Letter to Shareholders
5:04pm
8-K
EX-99.1
y5wkokh8
22 Nov 23
BrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA to Discuss Confirmatory Phase 3 Trial for NurOwn® in ALS
6:03am
8-K
EX-99.1
2uwq uso4
14 Nov 23
BrainStorm Cell Therapeutics Announces Third quarter 2023 Financial Results and Provides Corporate Update
12:00am
8-K
EX-99.1
js6mfmjvbocr qflxw
24 Oct 23
BrainStorm Cell Therapeutics Announces Strategic Realignment
7:30am
8-K
EX-99.1
u9w9ds h6oyamqptr
14 Aug 23
BrainStorm Cell Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
7:21am
8-K
EX-99.1
gisw8jd2ma6w8su21
19 Jul 23
Brainstorm Cell Therapeutics Announces Pricing of $7.5 Million Registered Direct Offering
4:05pm
8-K
EX-99.1
1kse7mkkpg154l
20 Jun 23
BrainStorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee Chair
5:01pm
8-K
EX-99.1
740s71kr
6 Jun 23
Regulation FD Disclosure
8:58am
8-K
EX-99.1
3fpvefl23pg4johj7
15 May 23
BrainStorm Cell Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
7:15am